[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 54, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 66, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 979215, "exercisedValue": 0, "unexercisedValue": 5922}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 612510, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark S. Forman M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 380965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Roy M. Gonzales CPA, M.B.A.", "age": 48, "title": "Senior VP of Finance and Principal Financial & Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Ms. Snehal  Naik Ph.D.", "title": "Senior VP of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathy  Ogilvie Ph.D.", "title": "Senior VP of Translational & Nonclinical Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.99, "open": 10.02, "dayLow": 9.88, "dayHigh": 10.15, "regularMarketPreviousClose": 9.99, "regularMarketOpen": 10.02, "regularMarketDayLow": 9.88, "regularMarketDayHigh": 10.15, "payoutRatio": 0.0, "beta": 1.236, "forwardPE": -4.6511626, "volume": 292227, "regularMarketVolume": 292227, "averageVolume": 4105722, "averageVolume10days": 1479110, "averageDailyVolume10Day": 1479110, "bid": 9.94, "ask": 10.04, "bidSize": 8, "askSize": 4, "marketCap": 713586432, "fiftyTwoWeekLow": 0.783, "fiftyTwoWeekHigh": 10.548, "allTimeHigh": 47.251, "allTimeLow": 0.783, "fiftyDayAverage": 6.2355, "twoHundredDayAverage": 3.027365, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 530972384, "profitMargins": 0.0, "floatShares": 60108235, "sharesOutstanding": 71358638, "sharesShort": 6151028, "sharesShortPriorMonth": 1402079, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.0862, "heldPercentInsiders": 0.04113, "heldPercentInstitutions": 0.68517, "shortRatio": 0.7, "shortPercentOfFloat": 0.0916, "impliedSharesOutstanding": 71358638, "bookValue": 2.683, "priceToBook": 3.727171, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -106607000, "trailingEps": -1.49, "forwardEps": -2.15, "enterpriseToEbitda": -4.56, "52WeekChange": 2.9682539, "SandP52WeekChange": 0.1326145, "quoteType": "EQUITY", "currentPrice": 10.0, "targetHighPrice": 21.0, "targetLowPrice": 9.0, "targetMeanPrice": 15.14286, "targetMedianPrice": 14.0, "recommendationMean": 1.375, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 192638000, "totalCashPerShare": 2.7, "ebitda": -116438000, "totalDebt": 10024000, "quickRatio": 17.154, "currentRatio": 17.861, "debtToEquity": 5.238, "returnOnAssets": -0.28465, "returnOnEquity": -0.45352, "freeCashflow": -47460248, "operatingCashflow": -87752000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VTYX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1764366484, "regularMarketTime": 1764352801, "exchange": "NMS", "messageBoardId": "finmb_672535556", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.100102395, "regularMarketPrice": 10.0, "cryptoTradeable": false, "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1634823000000, "postMarketChangePercent": -0.20000458, "postMarketPrice": 9.98, "postMarketChange": -0.020000458, "regularMarketChange": 0.010000229, "regularMarketDayRange": "9.88 - 10.15", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 4105722, "fiftyTwoWeekLowChange": 9.217, "fiftyTwoWeekLowChangePercent": 11.771392, "fiftyTwoWeekRange": "0.783 - 10.548", "fiftyTwoWeekHighChange": -0.54800034, "fiftyTwoWeekHighChangePercent": -0.051953007, "fiftyTwoWeekChangePercent": 296.82538, "earningsTimestamp": 1762462800, "earningsTimestampStart": 1762462800, "earningsTimestampEnd": 1762462800, "earningsCallTimestampStart": 1715286600, "earningsCallTimestampEnd": 1715286600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.49, "epsForward": -2.15, "epsCurrentYear": -1.44429, "priceEpsCurrentYear": -6.923817, "fiftyDayAverageChange": 3.7645001, "fiftyDayAverageChangePercent": 0.60372066, "twoHundredDayAverageChange": 6.9726353, "twoHundredDayAverageChangePercent": 2.3032026, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-21", "averageAnalystRating": "1.4 - Strong Buy", "displayName": "Ventyx Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-11-29"}]